CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEunpyeong St. Mary's Hospital
About this trial
This study is a multicenter, retrospective registry study using the CHATEAU Registry. The study will evaluate patients who underwent transcatheter aortic valve replacement between January 2021 and December 2025. The purpose of the study is to assess clinical outcomes and valve performance after TAVR in real-world practice, with a focus on procedural strategies, valve-related factors, and long-term outcomes. Patient clinical information, imaging findings, procedural data, echocardiographic results, and follow-up outcomes will be collected from existing medical records. No additional intervention, treatment, or study-specific visit will be performed.
Eligibility criteria
Qualifiers
Adults (≥18 years of age).
Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers.
TAVR performed between January 1, 2021 and December 31, 2025.
Availability of baseline procedural and follow-up clinical data in the institutional registry or medical records.
Disqualifiers
Patients with insufficient clinical or procedural data for outcome assessment.
Trial design
Treatments tested in this trial
- Transcatheter Aortic Valve Replacement
Treatment groups
4,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov